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Abstract 
Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) type I and II is a rare and 
life-threatening disease caused by SERPING1 gene mutations. Previous genetic studies indicated a wide 
spectrum of disease-associated variants in the SERPING1 gene and often lack of correlation with 
patient’s phenotypes. The aim of this study was to evaluate the presence, type, and localization of mu-
tations in the SERPING1 gene in 41 Polish patients with C1-INH-HAE and their relation with case/
family history, type of C1-INH-HAE, fC1-INH, age of onset, and disease severity. Sanger sequencing 
and MLPA method were used for detection of disease-associated variants. In 34 (82.9%) patients, mu-
tations located in various regions of SERPING1 gene were revealed. The detected alterations in patients 
with C1-INH-HAE type I differed and were positioned in various exons/introns of the SERPING1 gene. 
The most frequent disease-associated variants appeared in exon 3 (especially in type I) and in exon  
8 (type I and II). Out of 20 different disease-causing variants, 9 were not previously described. We did 
not find any relation between the type and location of the mutations and no type of features included 
in phenotype evaluation of the patients, such as case and family history, type of C1-INH-HAE, age of 
onset, biochemical parameters, or severity of disease. 
Key words: hereditary angioedema, C1-inhibitor, SERPING1, disease-associated variants. 
(Cent Eur J Immunol 2020; 45 (3): 301-309)
Introduction 
Hereditary angioedema due to C1-inhibitor deficiency 
(C1-INH-HAE) type I and II is a rare and life-threatening 
disease caused by SERPING1 gene mutations inherited as 
an autosomal dominant trait with incomplete penetrance [1, 
2]. After initial recognition in the 80-s, the mutation of SER-
PING1 gene encoding C1-inhibitor (C1-INH) is responsible 
for C1-INH-HAE [3, 4], and introducing genetic studies in 
patients with C1-INH-HAE [5] has become an essential part 
of molecular researches conducted on this disease [4, 6, 7]. 
Previous genetic studies indicated a wide spectrum of dis-
ease-associated variants in the SERPING1 gene and often 
lack of correlation with the phenotype in patients with this 
disease [8-11]. Over 500 different SERPING1 mutations [4] 
in patients with C1-INH-HAE have been detected and de-
scribed according to the Human Genome Mutation Database 
(HGMD) (http://www.hgmd.cf.ac.uk/ac/index.php). 
The aim of our study was to evaluate the presence, 
type, and localization of the disease-associated variants in 
the SERPING1 gene in Polish patients with C1-INH-HAE 
type I and type II [12] and their relation with patients’ 
phenotype as well as laboratory tests (fC1INH: C1-INH 
function, aC1INH: antigenic C1-INH) in the context of de-
tected disease-associated variants in the SERPING1 gene. 
Material and methods 
The study included 41 patients with C1-INH-HAE reg-
istered in Poland (31 females, 10 males, aged 4-75 years 
old) from 31 families [12]. 34 patients (82.9%) presented 
with type I, and 7 patients (17.1%) with type II of C1-
INH-HAE. Family history was negative for 16 patients. 
In 19 cases, the course of disease was severe (score 3), in 
19 – it was moderate (score 2), in 2 – light (score 1), and 
1 patient was asymptomatic (score 0, 4-year-old child with 
fC1-INH of 76%). 
The diagnosis of C1-INH-HAE was based on the case 
and family history, examination during the angioedema 
attack, assessment of disease severity with scoring 0-3 
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(0 – asymptomatic, 1 – mild, max. 6 events/year, 2 – max. 1 
event/month, 3 – more than 12 events/year), and estimation 
of aC1-INH and aC4 serum level and C1-INH function in 
plasma (fC1-INH). The fC1-INH was measured by chro-
motimer (Berichrom-AT, Bering) C1-inhibitor assay (Dade 
Behring). aC1-INH and aC4 were measured by nephelome-
try (Dade Behring). The biochemical diagnosis of C1-INH-
HAE patients was performed during remission of symp-
toms and based on evaluation of C1-INH serum level and 
C1-INH function in plasma [1, 5], which allowed to define 
the phenotype of C1-INH-HAE as type I and II [13-15]. 
Genotyping methods: From each patient, the total 
DNA was extracted from 300 µl of collected blood sam-
ple by nucleic acid isolation system QuickGene-Mini80 
with DNA blood kit (Kurabo Industries Ltd., Japan) ac-
cording to manufacturers’ protocol. The variation in 
the SERPING1 gene coding sequence was detected by 
Sanger sequencing method (Applied Biosystems 3500 
Genetic Analyzer). The SERPING1 gene coding se-
quence was checked against the reference sequence No. 
ENST00000278407.8. Separate analyzes included all 
8 exons of the gene. Initially, the PCR amplification was 
performed with the Hot Start Color Perpetual Taq DNA 
Polymerase kit (EURx Ltd., Poland). The PCR reaction was 
carried out in a mixture of 25 µl containing 100 ng DNA, 
200 µM dNTP, 1 × Pol Buffer B, 2 × U Hot Start Perpetu-
al Taq DNA polymerase, and 800 nM of primers for each 
exon. The sequences of the primers are shown in Table 1. 
 For exon 3 and 8, an additional 5% DMSO was used. PCR 
reaction was performed consisting of denaturation at 95°C 
for 30 seconds, annealing at primers’ dependent temperature 
(Table 1) for 30 seconds, and extension at 72°C for 45 sec-
onds, 35 cycles. There was an initial 10-minute denaturation 
at 95°C and a final extension at 72°C for 5 minutes. The PCR 
products were purified from unincorporated dNTPs and 
primers prior to the sequencing reaction by Exo-BAP Kit 
(EURx Ltd., Poland) according to manufacturers’ protocol. 
The final sequencing was performed with BigDye Termi-
nator v3.1 Cycle Sequencing kit (Thermo Fisher Scientific 
Inc.), and the products were cleaned up with ethanol precip-
itation and analyzed by Applied Biosystems 3500 Genetic 
Analyzer. The impact of newly detected sequence variants 
was predicted in silico by MutationTaster [16]. 
For the patients without point mutations and small de-
letions/insertions in the SERPING1 gene sequence, MLPA 
(Multiple Ligation Dependent Probe Amplification) anal-
ysis of large deletion/insertion was performed. SALSA 
MLPA Probemix P243-B1 SERPING1-F12 (MRC, Hol-
land) was used according to manufacturers’ procedure, 
with a fragment analysis by capillary electrophoresis on 
the Applied Biosystems 3500 Genetic Analyzers instru-
ment. The data were analyzed by MLPA analysis software 
(Coffalyser.Net). Statistical analysis of the relationship be-
tween the location of detected pathogenic variants and var-
ious clinical parameters was carried out by correspondence 
analysis using Kruskal-Wallis test and χ2 test depending on 
the examined parameter. 
All individual patients’ data were obtained and pro-
cessed according to patient’s consent, approved by the Eth-
ical Committee of the Jagiellonian University in Krakow 
(KBET 104/B/2014, dated May 22, 2014). 
Results 
In 28 (68.3%) patients with C1-INH-HAE, the ex-
istence of disease-associated variants in the SERPING1 
gene nucleotide sequence (Table 2A) was confirmed us-
ing direct Sanger sequencing method, and in 6 patients 
Table 1. Primers used for Sanger sequencing analysis of coding region of SERPING1 gene (reference sequence No. 
ENST00000278407.8)
Exon 
(exon ref No. in Ensembl) 




1. ENSE00001941568 F: 5’-CAC CTA CCA GGG GAT TTG G-3’ 
R: 5’-ACC CCC TCC CTA GAC CTC TT-3’ 
319 bp 58°C
2. ENSE00002142743 F: 5’-TGG GGA AAA CAA AAC AGA GG-3’ 
R: 5’-CGG AGC CTG AAG GGT TAA T-3’ 
346 bp 56°C
3. ENSE00003463488 F: 5’-CCA CAC CTT CTC TTC CTG CT-3’ 
R: 5’-CAT GGC TTT GTA AGT GTC TGG A-3’
668 bp 59°C
4. ENSE00003528440 F: 5’-CTC CAT TCC AGC CTG GTC-3’ 
R: 5’-GCT CCA ACA TTC CCT CTG TC-3’ 
328 bp 58°C
5. ENSE00003567744 F: 5’-GCA TGC TCA CTC TCA AAT CG-3’ 
R: 5’-GGG TTA AGT GGG CTT TG-3’ 
361 bp 56°C
6. ENSE00003499999 F: 5’-GGA TCT CAA TGT CCC TGC AC-3’ 
R: 5’-TAC CCC AAA ATG ATG GGA CT-3’ 
330 bp 58°C
7. ENSE00003682693 F: 5’-GCA GGA CAG CAT TGT GAC AG-3’ 
R: 5’-CAG GAC AAA CTG AGA TTA TGG ATG-3’
419 bp 58°C
8. ENSE00001769777 F: 5’-ATG TAA TCT GGC AAA CAA GGG AAG-3’ 
R: 5’-ACA AAG GCA AAG CAG AGA AAG TC-3’ 
679 bp 59°C
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(14.6%) with MLPA method (Table 2B). All together, 
we found disease-associated variants in exons/introns of 
SERPING1 in 34 from 41 individuals (82.9%). In the 
remaining 7 cases (17.1%), there were no quantitative 
changes or pathogenic variants in the coding sequence of 
SERPING1 gene. 
Among 34 patients with confirmed disease-associated 
variants in the SERPING1 gene, 27 individuals were diag-
nosed with C1-INH-HAE type I and 7 with C1-INH-HAE 
type II. In 31 cases, the course of illness was moderate/
severe (score 2-3). In 2 cases, the course of illness was 
slight (score 1) and in 1 case (a 4-year-old boy with fC1-
INH of 65%, carrying gross duplication incl. exon 5-6 in 
the SERPING1 gene) was without symptoms of the illness 
(Table 2B). Main clinical features of analyzed patients 
with detected disease-associated variants are presented in 
Supplementary Table 1.
Overall, we identified 20 different disease-associat-
ed variants in the SERPING1 gene sequence by Sanger 
sequencing analysis, out of which, 13 were found in pa-
tients without early familial history of the disease. Among 
20 types of detected sequence variants (Table 2A), 11 were 
previously described and could be found in the HGMD. 
They were classified pathogenic due to their disruption 
of splice regions, reporting as nonsense variants as well 
as missense variants, with well-established impact on 
C1-INH protein. Furthermore, we detected 9 novel dis-
ease-associated variants (not yet described), representing 
almost half of detected changes, and considered deleterious 
based on in silico predictions. The impact of newly detect-
ed sequence variants was predicted by MutationTaster [16]. 
For all detected variants, the prediction analysis showed 
their potential disease-causing impact (Table 2A). Fur-
thermore, in some cases (families II, XII), the pathogenic 
impact of detected variants was confirmed by its family in-
cidence. In cases No. 18 and 25, the variants were consid-
ered as variants probably leading to C1-INH-HAE because 
of the results of in silico prediction, but also de novo occur-
rence along with phenotypic symptoms of C1-INH-HAE. 
Five of detected variants were frameshift variants, detected 
in exon 3-5 (cases No. 3-5, 19, 32, 39, 40), which in all 
cases led to translation shifting to another reading frame 
and establishing premature STOP codons. Moreover, the 
in-frame deletions/insertions variant was found in exon 
3 (cases No. 20 and 21), with the pathogenicity prediction 
in silico and observed by disrupting of the protein func-
tion and lowering the activity of C1-INH in patients’ blood 
samples. Single cases of the nonsense variant (case No. 
34), missense variant (case No. 18), and deletion in the 
5’ untranslated regions (UTR) (case No. 25) were also 
detected. All disease-associated variants were present in 
the heterozygous state. In all patients with C1-INH-HAE 
type II, the disease-associated variants described earlier 
as related to type II (missense point mutation in Arg466, 
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an abdominal attack. Four individuals had a positive fami-
ly history. All these patients had the same type of polymor-
phism in exon 8: c.1438G>A (p.Val480Met). 
We did not find significant relations between the loca-
tion of disease-associated variants in the SERPING1 gene 
and aC1-INH, fC1-INH, or aC4 parameters. Moreover, 
the analysis of 17 patients with a severe course of illness 
did not reveal any correlations with the type or location of 
disease-associated variants. The early onset of symptoms 
(< 10 yrs.) was noted in 34.1% of patients. Till the age of 
18, 80.5% of patients were symptomatic. In patients with 
an early age of onset of C1-INH-HAE, type I was domi-
nating. There was no correlation between the location of 
disease-associated variants and the age of manifestation of 
the disease symptoms, family history, and the location of 
first edema. Most of the patients (74%) revealed symptoms 
of illness below 14 yrs. The abdomen was the most fre-
quent location of first symptoms of C1-INH-HAE < 18 yrs. 
The most often disease-associated variations in the 
SERPING1 gene was located in exon 8. Among 13 pa-
tients with a disease-associated variant in this region of the 
SERPING1 gene, we observed 7 patients with C1-INH-
HAE type II and 6 patients with C1-INH-HAE type I. 
In all patients with type II, missense point mutation in 
Table 3. Clinical characteristic 7 of 41 (17.1%) patients without confirmation of disease-associated variants by Sanger 

























V 9 F 23 0.06 19.4 0.04 I Yes 3 4/abdomen exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state
XIII 22 M 67 0.08 47 0.12 I No 1 20/foot exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state
XIV 23 F 49 0.048 13.6 0.11 I Yes 2 15/abdomen exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state
XV 24 F 53 0.048 23 0.07 I No 2 5/abdomen exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state
XII 26 F 47 0.1 46 0.07 I Yes 2 24/abdomen exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state
XVIII 27 F 34 0.02 30.4 0.03 I Yes 3 10/abdomen exon 8: rs4926. 
c.1438G>A (p.Val480Met) 
in heterozygous state













aC1-INH – serum level of C1-INH (normal range, 0.2-0.39 g/l), fC1-INH – activity of C1-INH in plasma (normal range, 70-130%), aC4 – serum level of C4 
(normal range, 0.1-0.4 g/l)
Gross duplication/deletion was identified by MLPA 
analysis in 6 patients (5 females and 1 boy) in two fami-
lies (Table 2B) and all suffered from C1-INH-HAE type 
I. Four patients had a positive family history, with mod-
erate/severe course of the disease. One patient (4-year-
old boy) was asymptomatic. The age of onset in the next 
5 patients ranged between 10 and 22 years old (mean, 13.8 
years old). In 2 cases, the location of first symptom con-
cerned the abdomen, the face was in 2 cases, and larynx 
in 1 patient. In 6 individuals with identified mutation in 
MLPA method, we found duplication incl. exon 5 and 
6 in 4 cases from family nr VII and deletion incl. exon 
8 in 2 individuals from family XXI. Quantitative changes 
described at genomic DNA level detected by MLPA are 
noted in the Human Gene Mutation Database as correlated 
with C1-INH-HAE. 
The analysis of 7 (17.1%) remaining patients (5 fe-
males and 2 males; mean age, 49.7 years old) with 
C1-INH-HAE without mutations in Sanger sequencing 
and MLPA genotyping is presented in Table 3. All patients 
were recognized as suffering from C1-INH-HAE type I, 
with moderate and severe course of illness. The age of on-
set of a disease ranged from 4 to 62 years old (mean, 21.1 
years old). In 5 cases, the first symptoms of disease were 
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PING1 gene. All other clinical and laboratory parameters, 
except for significantly higher mean age of onset of C1-
INH-HAE, did not differentiate this group in comparison 
with patients with disease-associated variants. 
It seems that C1-INH-HAE is a genetically complex 
disorder [1, 4], with participation genetic changes also in 
other than the SERPING1 gene, as genes encoding F12, 
aminopeptidases, angiopoetin1, plasminogen, or bradyki-
nin B2/B1 receptors genes, which also may modify the 
phenotype of C1-INH-HAE [1, 4, 24-29]. It is possible that 
more precise, modern methods of genome analysis, such as 
Next-Generation Sequencing (NGS) [2, 30-32], may dis-
close additional genetic changes and allow to increase the 
percentage of patients with disease-associated variants in 
C1-INH-HAE. Such possible confirmed NGS analysis was 
performed in another study [32] and in 7 our patients with 
negative genetic analysis, identified one case (female aged 
47 with type I C1-INH-HAE), another likely pathogenic 
missense variant in exon 4 of the SERPING1 (c.629T> C, 
p.(Leu210Pro) in heterozygous). 
Our results confirm the presence of large diversity of 
disease-associated variants in the SERPING1 gene locat-
ed in various regions for all 8 exons as well introns of 
the SERPING1 gene in patients with C1-INH-HAE. Dis-
ease-associated variants in the SERPING1 gene were locat-
ed mainly in exon 3 (36.4%) and in exon 8 (22.7%). The 
most frequent were missense variants (40.9%) and dele-
tion/insertion variants (18.2%), nonsense variants (13.6%), 
duplication (9.1%), gross duplication/deletions (9.1%), and 
splice region/regulatory variants (9.1%) (Table 2). These 
findings agree with previous data reported by other authors 
[2, 6, 10, 33, 34]. The cases of patients with C1-INH-HAE 
with homozygous C1-INH deficiency were also noted by 
other authors [35], which was not observed in our study. 
The location and type of disease-associated variants 
in patients of the same 6 family included into study were 
identical, which confirms previous observations of other 
authors [34], and what seems to be connected with the 
dominant type of inheritance with high penetrance. We 
confirmed that despite the same type and location of a dis-
ease-associated variant, the course of illness and the age 
of onset of C1-INH-HAE among the members of the same 
family was diverse, what indicates that the clinical phe-
notype does not directly correlate with the genotype, and 
the phenomenon of variable expressivity can be observed 
[2, 36]. It may suggest various personal (metabolic/envi-
ronmental) conditions having an essential influence on the 
course of disease in patients with C1-INH-HAE, which 
was emphasized by Ameratunga et al. [11], independently 
on genotype [1, 2, 8, 9, 26, 29]. 
Independently of the type of disease-associated vari-
ants in the SERPING1 gene in patients with C1-INH-HAE 
type I, low fC1-INH value and low aC1-INH serum level 
are characteristic diagnostic biomarkers. However in all 
7 patients with C1-INH-HAE type II, characteristic low 
values of fC1-INH and normal values of aC1-INH were 
Arg466 was found (Table 2A). In these patients, aC1-INH 
was normal or elevated, and ranged from 0.2 to 0.7 g/L 
(mean, 0.33 g/L), and the value of fC1-INH was low and 
ranged from 11.8 to 37.1% (mean, 23.3%). In remaining 
6 patients with type I, various disease-associated variants 
were located in whole sequence of exon 8 (Table 2A). In 
2 cases, splice region variants were found, and gross de-
letions incl. exon 8 were detected in another 2 cases. The 
aC1-INH in these patients was very low and ranged from 
0.04 to 0.09 g/L (mean, 0.06 g/L). Furthermore, the value 
of fC1-INH was very low and ranged from 0 to 22.4% 
(mean, 14.25%). The onset of C1-INH-HAE as well the 
course of illness did not differentiate the patients with dis-
ease-associated variant in exon 8 suffer with type II and 
I of C1-INH-HAE. 
Statistical analysis revealed significant relationship 
only between the location of mutation in exon 8 and type 
II C1-INH-HAE (p = 0.01017). We did not find any rela-
tion between the type and location of disease-associated 
variants and the course of disease, location of symptoms, 
age of onset, family history, and the activity of C1-INH. 
Discussion 
C1-INH-HAE [1, 5, 9] is a rare and life-threatening 
disease, with an autosomal dominant trait. Currently, geno-
typing is very important diagnostic tool in patients suspect-
ed of C1-INH–HAE, especially in cases with no family 
history of the disease or relatives of patients with C1-INH-
HAE, without evident symptoms of C1-INH-HAE [2, 3]. 
The genetic research of this disease allows to search for 
new strategies of therapies [4, 11] as well as possible ex 
vivo gene correction in future [11, 19]. Over 500 mutations 
have been found until now in the SERPING1 gene, which 
are associated with C1-INH-HAE, according to the Human 
Genome Mutation Database [4]. 
The presented results are the first genetic studies in 
Polish patients with C1-INH-HAE type I and II [12]. Using 
classic genotyping by Sanger sequencing and quantitative 
MLPA analysis, we observed the presence of disease-asso-
ciated variants in 34 out of 41 patients (82.9%), according 
to previous data concerning other European populations 
[7, 10, 20-23]. 
In the remaining 7 patients (17.1%), no disease-asso-
ciated variants in the SERPING1 gene were found. In all 
these patients, polymorphism: c.1438G>A (p.Val480Met) 
in exon 8 was present (Table 3). However, the frequency 
of this polymorphism is quite high in the general popu-
lation (according to Ensembl database, the frequency of 
variant c.1438A is 27%, rs4926). Until now, this poly-
morphism has not been related to C1-INH-HAE (ClinVar: 
RCV000288563.1, RCV000616583.1 – clinical signifi-
cance: benign), but there may be preliminary observation 
indicating the predisposition of people with this variant 
to C1-INH-HAE type I unrelated to the presence of dis-
ease-associated variants in encoding sequence of the SER-
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mRNA transcription or secretion of C1-INH in the serum, 
or may decrease the catabolism of aC1-INH elevated usu-
ally in patients with C1-INH-HAE [35, 41]. 
Better understanding of the pathomechanism leading to 
the development of these two different types of C1-INH-
HAE [1, 4, 11, 38] may help to explain the differences in 
values of aC1-INH serum level and fC1-INH caused by 
diverse genetic changes. At last, it may also help to under-
stand various cases, such as those described by Jasenack 
et al. [42], who presented 7 individuals from one family 
with C1-INH HAE type I with an unusual novel mutation 
of SERPING1 gene in exon 8, in the region typical for 
a mutation associated with type II. 
It is generally known and accepted that in patients 
with C1-INH-HAE despite the same mutation, the course 
of disease is different [1, 2, 4, 8, 9, 43] and the frequency 
and location of symptoms of the disease undergo changes 
in the same patient. Furthermore, the history in some pa-
tients indicates that the period of severe symptoms is fol-
lowed by a long remission without an evident reason and 
without the influence on aC1-INH and fC1-INH values. 
The question is why some people, despite very low values 
of aC1-INH and fC1-INH, are asymptomatic or live for 
a long time without symptoms. All these facts seem to in-
dicate that C1-INH-HAE is a disorder with very composed 
pathomechanism, whose symptoms are related not only to 
genetic changes but also to additional unspecific factors 
disturbing homeostasis of the human body [4, 11, 38]. 
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value is more associated with the activity of C1-INH-HAE 
symptoms, as suggested by others authors [4, 38] and 
confirmed in our study in only one case of asymptomatic 
4-years-old boy, with identified gross duplication incl. exon 
5 and 6 and with close to normal value of fC1-INH of 65%. 
It seems that an impact of additional, triggering factors that 
influence disease-severity are only essential for the provo-
cation of angioedema attack in patients with C1-INH-HAE. 
Our findings confirm previous reports [1, 5, 8, 9, 11] 
that most patients with C1-INH-HAE reveal first symp-
toms of illness before the age of 14, and that C1-INH-HAE 
type I as well as positive family history dominates in this 
group of patients. According to some authors [8, 39], the 
early onset of C1-INH-HAE often predisposes to a severe 
course of illness, but in our patients with severe course of 
disease, the early onset (< 10 years) was noted only in 50% 
of cases with type I and type II C1-INH-HAE. 
A very interesting group constitutes the patients with 
disease-associated variants in the SERPING1 gene lo-
cated in exon 8, focusing the cases with type I and type 
II C1-INH-HAE, for which the mechanisms regulating 
functional activity and antigenic level of C1-INH are dif-
ferent [4]. In all these cases, the value of fC1-INH was 
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affect the synthesis and secretion of C1-INH. However, in 
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